Libbey S. O′Farrell

1.2k citations

17 papers · 648 indexed · 2 hit papers · h-index 10

Endocrinology, Diabetes and Metabolism top 5%
Physiology top 10%
Molecular Biology
Pharmacology top 10%
Surgery

Co-authors: Tamer Coşkun Axel Haupt Shweta Urva Daniel A. Briere Corina Loghin Charles Benson Andrew C. Adams Susan L. DuBois
Topics: Diabetes Treatment and Management (6 papers)Pharmacology and Obesity Treatment (5 papers)Adipose Tissue and Metabolism (5 papers)
Cited by: Endocrinology, Diabetes and Metabolism Endocrine and Autonomic Systems Physiology
Journals: Cell Cell Metabolism Diabetes
Partner nations: United States Germany Japan

In The Last Decade

Libbey S. O′Farrell

16 papers receiving 633 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

2022 180 citations Tamer Coşkun, Shweta Urva et al. Cell Metabolism profile →
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation

2025 18 citations Éric Ravussin, Guillermo Sánchez‐Delgado et al. Cell Metabolism profile →

Peers

Countries citing papers authored by Libbey S. O′Farrell

Since Specialization

Citations

This map shows the geographic impact of Libbey S. O′Farrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libbey S. O′Farrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libbey S. O′Farrell more than expected).

Fields of papers citing papers by Libbey S. O′Farrell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Libbey S. O′Farrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libbey S. O′Farrell. The network helps show where Libbey S. O′Farrell may publish in the future.

Co-authorship network of co-authors of Libbey S. O′Farrell

This figure shows the co-authorship network connecting the top 25 collaborators of Libbey S. O′Farrell. A scholar is included among the top collaborators of Libbey S. O′Farrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Libbey S. O′Farrell. Libbey S. O′Farrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidationbreakdown → 2025 ·Cell Metabolism ·Éric Ravussin,Guillermo Sánchez‐Delgado,Corby K. Martin,Robbie A. Beyl,Frank L. Greenway,Libbey S. O′Farrell,William C. Roell,(unknown),Jing Li,Hiroshi Nishiyama,Axel Haupt,Edward Pratt,Shweta Urva,Zvonko Miličević,Tamer Coşkun	18
2	Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept 2025 ·Molecular Metabolism ·Daniel A. Briere,Hongchang Qu,Katherine Lansu,Minxia M. He,Julie S. Moyers,Tamer Coşkun,Andrew Long,David Allen,Libbey S. O′Farrell,(unknown),Edward Pratt,(unknown),Lai Tham,(unknown),Jorge Alsina‐Fernandez,Kieren J. Mather,Axel Haupt,Shobha Bhattachar	4
3	849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide 2025 ·Diabetes ·Daniel A. Briere,A. Long,(unknown),Libbey S. O′Farrell,(unknown),Katherine Lansu,(unknown),Julie S. Moyers,Hongchang Qu	0
4	Characterization of LY3324954 a long-acting glucagon-receptor agonist 2024 ·Molecular Metabolism ·William C. Roell,Tamer Coşkun,Teayoun Kim,Libbey S. O′Farrell,Jennifer A. Martin,(unknown),(unknown),(unknown),Daniel J. Drucker,Kyle W. Sloop,(unknown),Jorge Alsina‐Fernandez,Kirk M. Habegger	2
5	GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice 2023 ·Diabetes ·(unknown),(unknown),Kyla Collins,Xinxin Yu,Brian A. Droz,(unknown),Jessica L. Friedrich,(unknown),Debra L. Konkol,Libbey S. O′Farrell,Hana E. Baker,Tamer Coşkun,Philipp E. Scherer,Christine M. Kusminski,Michael E. Christe,Kyle W. Sloop,Ricardo J. Samms	8
6	The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying 2023 ·Diabetes Obesity and Metabolism ·Shweta Urva,Libbey S. O′Farrell,Yu Du,(unknown),(unknown),Hongchang Qu,Jorge Alsina‐Fernandez,Axel Haupt,Zvonko Miličević,Tamer Coşkun	19
7	Glucose‐dependent insulinotropic polypeptide counteracts diet‐induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin‐responsive and proopiomelanocortin neurons in the arcuate nucleus 2023 ·Diabetes Obesity and Metabolism ·(unknown),Lei Wang,(unknown),Masakazu Takeuchi,Libbey S. O′Farrell,Tamer Coşkun,(unknown),Daisuke Yabe,Yusaku Iwasaki,Yutaka Seino,Toshihiko Yada	14
8	LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptbreakdown → 2022 ·Cell Metabolism ·Tamer Coşkun,Shweta Urva,William C. Roell,Hongchang Qu,Corina Loghin,Julie S. Moyers,Libbey S. O′Farrell,Daniel A. Briere,Kyle W. Sloop,Melissa K. Thomas,Valentina Pirro,David B. Wainscott,Francis S. Willard,(unknown),LaRonda L. Morford,Yu Du,Charles Benson,Ruth E. Gimeno,Axel Haupt,Zvonko Miličević	180
9	639-P: GIP Receptor Agonism Enhances Weight Loss from Either a Biased or an Unbiased GLP-1 Receptor Agonist in DIO Mice 2021 ·Diabetes ·Matthew P. Coghlan,Libbey S. O′Farrell,Aaron D. Showalter,David B. Wainscott,Cynthia Stutsman,Guemalli R. Cardona,Over Cabrera,Jorge Alsina‐Fernandez,Francis S. Willard,Kyle W. Sloop,Tamer Coşkun	2
10	679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes 2021 ·Diabetes ·Tamer Coşkun,Julie S. Moyers,William C. Roell,Libbey S. O′Farrell,Ajit Regmi,Xiaoping Ruan,Aaron D. Showalter,Kyle W. Sloop,David B. Wainscott,Francis S. Willard,James Ficorilli,Over Cabrera,Shweta Urva,(unknown),Lili Guo,Jorge Alsina‐Fernandez,Hongchang Qu	9
11	The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists 2020 ·Diabetes Obesity and Metabolism ·Shweta Urva,Tamer Coşkun,Corina Loghin,Xuewei Cui,(unknown),Libbey S. O′Farrell,Daniel A. Briere,Charles Benson,Michael A. Nauck,Axel Haupt	92
12	The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis 2019 ·Molecular Metabolism ·Patrick J. Antonellis,Brian A. Droz,Richard Cosgrove,Libbey S. O′Farrell,Tamer Coşkun,James W. Perfield,Steven M. Bauer,Mark Wade,(unknown),Joseph T. Brozinick,Andrew C. Adams,Ricardo J. Samms	30
13	Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation 2018 ·Cell ·Yongguo Li,(unknown),(unknown),Monja Willershäuser,Josefine Reber,Angelos Karlas,Sanna Laurila,Minna Lahesmaa,Mueez U-Din,(unknown),Kirsi A. Virtanen,Tobias Fromme,Florian Bolze,Libbey S. O′Farrell,Jorge Alsina‐Fernandez,Tamer Coşkun,Vasilis Ntziachristos,Pirjo Nuutila,Martin Klingenspor	167
14	Fully Implantable Arterial Blood Glucose Device for Metabolic Research Applications in Rats for Two Months 2015 ·Journal of Diabetes Science and Technology ·(unknown),(unknown),(unknown),(unknown),(unknown),Libbey S. O′Farrell,(unknown),Amy L. Cox,Tamer Coşkun	17
15	Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones 2013 ·Molecular Metabolism ·Andrew C. Adams,Tamer Coşkun,Christine C. Cheng,Libbey S. O′Farrell,Susan L. DuBois,Alexei Kharitonenkov	68
16	Activation of Prostaglandin E Receptor 4 Triggers Secretion of Gut Hormone Peptides GLP-1, GLP-2, and PYY 2012 ·Endocrinology ·Tamer Coşkun,Libbey S. O′Farrell,Samreen K. Syed,Daniel A. Briere,Lisa S. Beavers,Susan L. DuBois,(unknown),(unknown),David G. Barrett,Alexander M. Efanov	16
17	Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity 2011 ·ACS Medicinal Chemistry Letters ·Cynthia D. Jesudason,James E. Baker,(unknown),(unknown),Libbey S. O′Farrell,Gregory Gaich,Minxia M. He,Steven D. Kahl,Aidas Kriauciunas,Mark L. Heiman,(unknown),Christopher J. Rito,Julie Satterwhite,Frank C. Tinsley,(unknown),Anthony J. Shuker	2

About Libbey S. O′Farrell

Libbey S. O′Farrell is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Physiology, having authored 17 papers that have together received 648 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (6 papers), Pharmacology and Obesity Treatment (5 papers) and Adipose Tissue and Metabolism (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (299 citations), Endocrine and Autonomic Systems (81 citations) and Physiology (256 citations). Libbey S. O′Farrell has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Tamer Coşkun, Axel Haupt, Shweta Urva, Daniel A. Briere, Corina Loghin, Charles Benson, Andrew C. Adams, Susan L. DuBois, Jorge Alsina‐Fernandez and Hongchang Qu. Their work appears in journals such as Cell, Cell Metabolism and Diabetes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact